Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Menorrhagia, Increased mean platelet volume, and Impaired ADP-induced platelet aggregation; and common findings: Abnormal bleeding tendency (abnormal bleeding) and Low platelet count (thrombocytopenia). 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 6 | Abnormal bleeding tendency (abnormal bleeding), Impaired platelet aggregation, Increased mean platelet volume |
FLI1 encodes Fli-1 proto-oncogene, ETS transcription factor (452 aa). Sequence-specific transcriptional activator. Recognizes the DNA sequence 5'-C[CA]GGAAGT-3' Highest expression in Spleen (90.1 TPM) and Lung (43.0 TPM).
Bleeding disorder, platelet-type, 21 has been associated with mutations in the FLI1 gene on chromosome 11.
The FLI1 protein participates in CEBPA gene:RUNX1:SPI1:GATA2:TAL1:FLI1:MYB, RUNX1, SPI1 (PU.1), GATA2, TAL1 (SCL), FLI1, and MYB bind the CEBPA promoter, and CEBPA gene transcription is enhanced by RUNX1, SPI1 (PU.1), GATA2, TAL1 (SCL), FLI1, MYB, LEF1, and CEBPA pathways.
FLI1 is classified as a druggable target (Clinically Actionable and Transcription Factor categories) with score 26.1.
Genetic testing for FLI1 is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for bleeding disorder, platelet-type, 21 has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 2 common features.
No clinical trials have been registered for bleeding disorder, platelet-type, 21.
3 publications have been identified in PubMed for bleeding disorder, platelet-type, 21. Research spans Diagnostic / Biomarker (33%), Case Report / Case Series (33%), and Basic Science / Preclinical (33%).
Gök V (2025). [PMID: 40488176](https://pubmed.ncbi.nlm.nih.gov/40488176/). *Res Pract Thromb Haemost*. [Case Report / Case Series]
Gabinaud E (2025). [PMID: 39744817](https://pubmed.ncbi.nlm.nih.gov/39744817/). *Haematologica*. [Basic Science / Preclinical]
Hassan E (2025). [PMID: 40486211](https://pubmed.ncbi.nlm.nih.gov/40486211/). *Res Pract Thromb Haemost*. [Diagnostic / Biomarker]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about bleeding disorder, platelet-type, 21
Skin | 3 | Alopecia, Eczematoid dermatitis, Psoriasiform dermatitis |